Will Sovaldi & Harvoni’s super-low distribution margins be addressed this year?

Gilead has attracted attention of the pharmaceutical distribution industry as planning to review the problem in distribution margins of ‘Sovaldi’ and ‘Harvoni,’ chronic hepatitis C treatments, which have super-low margins; it was known they are so low that the industry gets more deficits as selling them more.

It was known Gilead Sciences Korea recently decided to review the problem about their...